Perspective Therapeutics, Inc.
$4.55
▼
-0.23%
2026-04-21 05:54:00
www.perspectivetherapeutics.com
ASE: CATX
Explore Perspective Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$478.52 M
Current Price
$4.55
52W High / Low
$6.16 / $1.75
Stock P/E
—
Book Value
$2.79
Dividend Yield
—
ROCE
-47.66%
ROE
-41.65%
Face Value
—
EPS
$-1.41
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
163
Beta
1.87
Debt / Equity
1.57
Current Ratio
5.17
Quick Ratio
5.17
Forward P/E
-3.81
Price / Sales
576.11
Enterprise Value
$367.8 M
EV / EBITDA
-3.33
EV / Revenue
416.06
Rating
Strong Buy
Target Price
$13
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Glaukos Corporation | $123.8 | — | $7.27 B | — | -25.2% | -26.38% | $130.23 / $73.16 | $11.41 |
| 2. | NovoCure Limited | $12.67 | — | $1.44 B | — | -26.47% | -38.89% | $20.06 / $9.82 | $3.03 |
| 3. | Tactile Systems Technology, Inc. | $25.52 | 30.42 | $580.59 M | — | 12.57% | 8.77% | $37.77 / $8.61 | $9.76 |
| 4. | Bio-Rad Laboratories, Inc. | $302.22 | 10.88 | $8.04 B | — | 2.17% | 10.84% | $343.12 / $211.43 | $276.16 |
| 5. | Biomerica, Inc. | $2.18 | — | $6.74 M | — | -122.16% | -84.3% | $4.6 / $1.87 | $1.5 |
| 6. | Viemed Healthcare, Inc. | $9.66 | 24.97 | $372.9 M | — | 13.1% | 11.11% | $10.06 / $5.93 | $3.72 |
| 7. | Myomo, Inc. | $0.9 | — | $34.65 M | — | -47.54% | -86.24% | $4.99 / $0.6 | $0.3 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -39.83 M | -27.86 M | -24.04 M | -21.83 M | -20.89 M | — |
| Net Profit | -37.49 M | -25.97 M | -21.48 M | -18.18 M | -40.17 M | — |
| EPS in Rs | -0.33 | -0.23 | -0.19 | -0.16 | -0.35 | -0.21 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 10.79 M |
| Operating Profit | -113.56 M | -66.8 M | -40.94 M | -7.39 M |
| Net Profit | -103.12 M | -79.28 M | -46.51 M | -7.27 M |
| EPS in Rs | -0.91 | -0.7 | -0.41 | -0.06 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 266.97 M | 341.1 M | 97.89 M | 64.44 M |
| Total Liabilities | 59.94 M | 50.43 M | 22.71 M | 3.16 M |
| Equity | 207.03 M | 290.67 M | 75.18 M | 61.28 M |
| Current Assets | 148.39 M | 231.16 M | 16.84 M | 59.33 M |
| Current Liabilities | 28.68 M | 18.23 M | 15.66 M | 2.27 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -82.48 M | -18.29 M | -36.91 M | -7.71 M |
| Investing CF | 41.23 M | -218.93 M | 24.37 M | -0.28 M |
| Financing CF | 10.3 M | 289.38 M | 0.79 M | 0.06 M |
| Free CF | -95.23 M | -72.71 M | -37.98 M | -7.98 M |
| Capex | -12.75 M | -54.41 M | -1.07 M | -0.27 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | — | — |
| Earnings Growth % | -70.46% | -539.55% | — | — |
| Profit Margin % | — | — | -67.36% | — |
| Operating Margin % | — | — | -68.47% | — |
| Gross Margin % | — | — | 42.76% | — |
| EBITDA Margin % | — | — | -66.17% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-06-17 | 1:0.1 |